EMA Revises Draft Guidance for Proposed Immunoglobulin Biologics

The EMA published a third revision to its guideline for human normal immunoglobulin for intravenous use, covering biological data, pharmacokinetics, clinical trials and patient follow-up, as well as changes in the manufacturing process of previously authorized products.
Source: Clinical Trials Advisor